Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
about
Combination therapy with biologic agents in rheumatic diseases: current and future prospectsAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapyASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis.Treat-to-target in spondyloarthritis: implications for clinical trial designs.Advances in the management of psoriatic arthritis.Certolizumab pegol for the treatment of psoriatic arthritis.Treat to target in psoriatic arthritis-evidence, target, research agenda.Biologics in spondyloarthritis: TNFα inhibitors and other agents.Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Treating to target in psoriatic arthritis: how to implement in clinical practice.Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.Secukinumab for the treatment of psoriatic arthritis.Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies.Remission in psoriatic arthritis-where are we now?Implementation of protocolized tight control and biological dose optimization in daily clinical practice: results of a pilot study.Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis.Is spinal mobility in patients with spondylitis determined by age, structural damage, and inflammation?Treating to target in axial spondyloarthritis: defining the target and the arrow.[Treat-to-target (T2T) recommendation for patients with spondyloarthritis - translation into German].
P2860
Q28066250-DA3B109E-B5C5-4BB3-BA68-4461D6B1F514Q28074393-A97A031D-F2CC-452A-87DD-805A4E8020A1Q36366162-4FD024DE-BE9C-41F0-B78F-96BC32DB9D48Q37465518-5CBE13CD-270E-4156-B6EF-FC2B5AF136CDQ37713522-326C122F-F8D6-4E8B-8479-F80472A8CAADQ38223570-711BF029-C521-4395-9DD9-4BB4A389E009Q38227264-CD9B43E4-4B3F-4ED6-8EAA-03C200B97946Q38344194-596D52E8-72F9-4E47-9871-C37A099D6310Q38436516-350153C2-CFEF-4162-B889-48F04C5655C7Q38522331-D79FC19A-FD71-4ABB-A0C7-FE5F6CCB92C3Q38540408-91D4E9F9-AD9A-421D-9B6B-D385E1A1157DQ38661777-D08AE747-A9AB-43C3-AD7D-824EEF61C1C8Q38670583-CF987878-786E-4434-96C1-B2A5422003B5Q38690324-875F1F29-1564-463C-952B-7F8FFC048142Q38934405-92D71247-A555-4B57-B56D-0EF2E27042A1Q39135959-8E0A7CA7-B42E-45CC-B774-C0CB26E5E222Q47432586-F1C3B504-247E-4CF5-8213-4D250C3B96A2Q48035875-0124EE65-2559-4515-B77A-F3714B089376Q48641283-5CB5CB14-1B72-479B-BD9F-8913D12403C8Q50654485-3F52EF6B-A3B2-45EB-A1E8-CD5DB1CCD09AQ50985212-78BC6BFA-1597-41BB-9DE2-17EAD5459CE0Q52849042-875B215A-F76F-4412-A82C-5B606FFE693C
P2860
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treating axial and peripheral ...... endation in spondyloarthritis.
@en
Treating axial and peripheral ...... endation in spondyloarthritis.
@en-gb
Treating axial and peripheral ...... endation in spondyloarthritis.
@nl
type
label
Treating axial and peripheral ...... endation in spondyloarthritis.
@en
Treating axial and peripheral ...... endation in spondyloarthritis.
@en-gb
Treating axial and peripheral ...... endation in spondyloarthritis.
@nl
prefLabel
Treating axial and peripheral ...... endation in spondyloarthritis.
@en
Treating axial and peripheral ...... endation in spondyloarthritis.
@en-gb
Treating axial and peripheral ...... endation in spondyloarthritis.
@nl
P2093
P2860
P50
P1476
Treating axial and peripheral ...... endation in spondyloarthritis.
@en
P2093
A Kavanaugh
C Ritchlin
D van der Heijde
I Olivieri
J S Smolen
M Dougados
M M Schoels
M Rudwaleit
P2860
P304
P356
10.1136/ANNRHEUMDIS-2013-203860
P407
P5008
P577
2013-06-05T00:00:00Z
2014-01-01T00:00:00Z
P5875
P6179
1045086304